Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for ADI-001 in Rheumatoid Arthritis (RA). The expected timing is based on the latest available company guidance and may change.
10/16/25- First patient dosed. Preliminary data in H2 2026. 11/05/25:- RA Ph1 trial enrolling; testing two lymphodepletion regimens; clinical update expected H2 2026. 03/12/26:- RA Ph1 trial ongoing, testing two conditioning regimens; next clinical safety and activity update expected H2 2026. 05/13/26:- Ongoing Phase 1 RA trial assessing two lymphodepletion regimens; next safety and activity update expected H2 2026. 08/05/26:- PR No update.
Verification
Confirm timing and program details against the company announcement or filing.